Enterome

Summary

Seedtable Score

48

Locations

• Paris

Company Size

• 51 to 100

Last Stage Round

• Series F

Industry

• Biotech
• Deep Tech
• Health Tech

Insights

Enterome's focus on immunomodulatory drugs positions it well in the health and biopharma sectors, particularly in cancer and immune diseases. Based in Paris and operating on a B2B model, the company leverages research in immune system modulation to develop treatments that may complement existing therapies like chemotherapy and immunotherapies. Its specialized approach offers a competitive edge, potentially leading to more effective treatments, faster recovery times, and improved survival rates. Backed by investors such as The Leukemia & Lymphoma Society’s Therapy Acceleration Program and Nestlé Health Science, Enterome shows strong market confidence and strategic support, enhancing its growth prospects in the biotech landscape.

• 2023 Series F $3.2M

---

• 2020 Series E $52.1M

---

• 2017 Series D $34.8M

---

• 2016 Series C $15.9M

---

• 2014 Series B $12.0M

---

• 2012 Series A $8.2M

---

• 2011 Seed $1.6M

---

Investors

• Nestlé Health Science Series F

---

• Nestlé Health Science Series F

---

• The Leukemia & Lymphoma Society’s Therapy Acceleration Program Series F

---

• Seventure Partners Series E

---

• Seventure Partners Series D

---

• Omnes Capital Series D

---

• Nestlé Health Science Series D

---

• Nestlé Health Science Series D

---

• Seventure Partners Series C

---

• Omnes Capital Series C

---

• Nestlé Health Science Series C

---

• Nestlé Health Science Series C

---

• Seventure Partners Series B

---

• Omnes Capital Series B

---

• Seventure Partners Series A

---

• Omnes Capital Series A

---

• Seventure Partners Seed

---